市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | JBIO | - | - |
AIStockmoo 评分
-0.4
| 分析师共识 | 0.0 |
| 内部交易活动 | 3.0 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.40 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Sofinnova Investments, Inc. | 31 Dec 2024 | 107,386 |
| Braidwell Lp | 31 Dec 2024 | 41,155 |
| Logos Global Management Lp | 31 Dec 2024 | 39,998 |
| Allostery Investments Lp | 31 Dec 2024 | 24,304 |
| Blackstone Inc. | 31 Dec 2024 | 14,273 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 93.80 | - | 1,062,326 | 99,646,179 |
| 累积净数量 | 1,062,326 | |||
| 累积净值 ($) | 99,646,179 | |||
| 累积平均购买 ($) | 93.80 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 28 Apr 2025 | 获得 (+) | 1,062,326 | 93.80 | 99,646,179 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合